02823nam a2200241   4500001000700000010001800007090001100025100004100036101000800077200013000085210006400215215002000279300004800299330188200347606003202229606003502261606003702296606003202333606001902365710006802384955001102452995011802463395507  a9789294974082  a395507  a20190617d2019       y0pory50      ba  aeng  aAn analysis of post-mortem toxicology practices in drug-related death cases in EuropebRecurso eletrónicoetechnical report  aLuxembourgcPublications Office of the European Uniond2019  a1 CD-ROMd12 cm  aFicheiro de 1,21 MB em formato PDF (52 p.).  aAcknowledgements. Executive summary. Background and objectives. Key findings. Limitations. Conclusions. Introduction. Part 1: Scoping study on national reference documents that address drug-related death toxicology investigations in Europe (28 EU Member States plus Norway and Turkey). 1.1. Objective and methods. 1.2. Findings. 1.2.1. Coverage of post-mortem toxicology in national and international guidelines. 1.2.2. Decision-making on the application of post-mortem forensic toxicological investigations in suspected drug-related deaths. 1.2.3. Pre-analytical management: sample collection, preservatives, storage of post-mortem specimens, preparation and extraction. 1.2.4 Calibration in the case of post-mortem specimens. 1.2.5. Standards for post-mortem screening and confirmatory analytical methods. 1.2.6. Analytical methods for new psychoactive substances in post-mortem specimens. 1.2.7. Interpretation and reporting of findings in forensic toxicology. 1.2.8. Certification of drug-related deaths. 1.3. Discussion. Part 2: Survey of practices — mapping the ‘typical’ or ‘standard’ toxicology practices in place in each country. 2.1. Objective. 2.2. Methods. 2.3. Results. 2.3.1 Characteristics of participating laboratories. 2.3.2. Collection of test material for toxicological analysis. 2.3.3. Laboratory equipment. 2.3.4. Analytical strategy. 2.3.5. Analytical strategy: classification. 2.3.6. Special analytical considerations and reporting. 2.3.7. Substance group coverage. 2.3.8. Collaboration/information Exchange. 2.3.9. Coverage of new psychoactive substances. 2.3.10. Suggestions for improvements. 3. Discussion and conclusions. 3.1 Interpreting drug-related death prevalence data against the background of toxicology standards and capacity in European countries. 3.2. Conclusions. 3.2.1. Consequences and priorities for public health. References.  aTOXICOLOGIA FORENSE9100154  aANÁLISE LABORATORIAL9326721  aANÁLISE DE VESTÍGIOS9320649  aTOXICODEPENDÊNCIA9225048  aEUROPA9326972  aEUROPEAN MONITORING CENTRE FOR DRUGS AND DRUG ADDICTION9351987  xOferta  104PJCD_302_00000000000000052022-06-066PJCD3029428423aPJcPJfPJ1CD302_37kPJCD302n2022-06-06o0rMOxOferta